9 Meters Biopharma Accounts Payable

9 Meters Biopharma (NMTR) currently reports a accounts payable of $4.2M as of March 2023. That compares with $1.9M in the prior-year period — up 121.3% year over year. Use the charts on this page to explore 9 Meters Biopharma's accounts payable history and peer comparisons.

9 Meters Biopharma's accounts payable increased from $1.9M to $4.2M — a 121.3% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

9 Meters Biopharma reported $4.2M in accounts payable as of March 2023. That compares with $1.9M in the prior-year period — up 121.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $4.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for 9 Meters Biopharma, and consider following NMTR for alerts when major investors trade the stock.

9 Meters Biopharma is classified in the Technology sector. On accounts payable, it currently shows $4.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing NMTR with unrelated industries.